Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together

Cancer

Volumn 88, Issue 11, 2000, Pages 2619-2628

  Wang, Tzu Hao ^a   Wang, Hsin Shih ^a   Soong, Yung Kwei ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Bcl 2 family; Cell cycle; JNK SAPK; p53; Paclitaxel

Indexed keywords

PACLITAXEL; PROTEIN BCL 2; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL CYCLE; CELL DEATH; CYTOTOXICITY; HUMAN; HUMAN CELL; MICROTUBULE; MITOSIS INHIBITION; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL DEATH; GENE EXPRESSION; HUMANS; MICROTUBULES; PACLITAXEL;

EID: 0034212385     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J     Document Type: Article

References (127)

1. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997;48:353-74.
2. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME, Huang Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 1993;7:563-8.
3. Li X, Gong J, Feldman E, Seiter K, Traganos F, Darzynkiewicz Z. Apoptotic cell death during treatment of leukemias. Leuk Lymphoma 1994;13(Suppl 1):65-70.
4. Havrilesky LJ, Elbendary A, Hurteau JA, Whitaker RS, Rodriguez GC, Berchuck A. Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet Gynecol 1995;85:1007-10.
5. Chang YF, Li LL, Wu CW, Liu TY, Lui WY, Peng FK, et al. Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 1996;77:14-8.
6. Gan Y, Wientjes MG, Schuller DE, Au JL. Pharmacodynamics of taxol in human head and neck tumors. Cancer Res 1996; 56:2086-93.
7. Yen WC, Wientjes MG, Au JL. Differential effect of Taxol in rat primary and metastatic prostate tumors: site-dependent pharmacodynamics. Pharm Res 1996;13:1305-12.
8. Fallo F, Pilon C, Barzon L, Pistorello M, Pagotto U, Altavilla G, et al. Effects of Taxol on the human NCI-H295 adreno-cortical carcinoma cell line. Endocr Res 1996;22:709-15.
9. Terzis AJ, Thorsen F, Heese O, Visted T, Bjerkvig R, Dahl O, et al. Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br J Cancer 1997; 75:1744-52.
10. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996;88: 1308-14.
11. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980;77: 1561-5.
12. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998;10:123-30.
13. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci USA 1993;90:9552-6.
14. Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1995;1:506-26.
15. Vasey PA, Jones NA, Jenkins S, Dive C, Brown R. Cisplatin, camptothecin, and Taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 1996;50:1536-40.
16. Wang TH, Wang HS. p53, apoptosis and human cancers. J Formos Med Assoc 1996;95:509-22.
17. Debernardis D, Sire EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 1997;57:870-4.
18. Fan S, Cherney B, Reinhold W, Rucker K, PM OC. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after Taxol or vincristine treatment. Clin Cancer Res 1998;4:1047-54.
19. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996;2:72-9.
20. Trielli MO, Andreassen PR, Lacroix FB, Margolis RL. Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific related mortality of transformed cells. J Cell Biol 1996;135: 689-700.
21. Safran H, King T, Choy H, Gollerkeri A, Kwakwa H, Lopez F, et al. p53 mutations do not predict response to paclitaxel/ radiation for nonsmall cell lung carcinoma. Cancer 1996;78: 1203-10.
22. Perego P, Romanelli S, Carenini N, Magnani I, Leone R, Bonetti A, et al. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. Ann Oncol 1998;9:423-30.
23. Vikhanskaya F, Vignati S, Beccaglia P, Ottoboni C, Russo P, D'Incalci M, et al. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp Cell Res 1998;241: 96-101.
24. Zaffaroni N, Silvestrini R, Orlandi L, Bearzatto A, Gornati D, Villa R. Induction of apoptosis by Taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells. Br J Cancer 1998;77: 1378-85.
25. Barboule N, Chadebech P, Baldin V, Vidal S, Valette A. Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene 1997; 15:2867-75.
26. Murphy M, Hinman A, Levine AJ. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev 1996;10:2971-80.
27. Zhang CC, Yang JM, White E, Murphy M, Levine A, Hait WN. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 1998;16:1617-24.
28. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, et al. High levels of p26BCL-2 oncoprotein retard Taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 1994;8:1960-9.
29. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 1997;11:253-7.
30. Gazitt Y, Rothenberg ML, Hilsenbeck SG, Fey V, Thomas C, Montegomrey W. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol 1998;13:839-48.
31. Liu JR, Fletcher B, Page C, Hu C, Nunez G, Baker V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol 1998;70:398-403.
32. Sumantran VN, Ealovega MW, Nunez G, Clarke MF, Wicha MS. Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 1995;55:2507-10.
33. Simonian PL, Grillot DA, Nunez G. Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bcl-XL and Bcl-2. Oncogene 1997;15: 1871-5.
34. Strobel T, Tai YT, Korsmeyer S, Cannistra SA. BAD partly reverses paclitaxel resistance in human ovarian cancer cells. Oncogene 1998;17:2419-27.
35. Strobel T, Swanson L, Korsmeyer S, Cannistra SA. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A 1996;93:14094-9.
36. Strobel T, Kraeft SK, Chen LB, Cannistra SA. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. Cancer Res 1998;58:4776-81.
37. Liu QY, Stein CA. Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression. Clin Cancer Res 1997;3:2039-46.
38. Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C. Cisplatin-and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol 1998; 53:819-26.
39. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS, Longo DL. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 1998;18:3509-17.
40. Blagosklonny MV, Giannakakou P, el-Deiry WS, Kingston DG, Higgs PI, Neckers L, et al. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 1997;57:130-5.
41. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995;92:4507-11.
42. Haldar S, Basu A, Croce CM. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res 1998;58:1609-15.
43. Roth W, Wagenknecht B, Grimmel C, Dichgans J, Weller M. Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. Br J Cancer 1998;77:404-11.
44. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996;56:1851-4.
45. Ibrado AM, Liu L, Bhalla K. Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells. Cancer Res 1997;57:1109-15.
46. Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, Leach SD, et al. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem 1998;273:30777-84.
47. Chang BS, Minn AJ, Muchmore SW, Fesik SW, Thompson CB. Identification of a novel regulatory domain in Bcl-X(L) and Bcl-2. EMBO J 1997;16:968-77.
48. Chen CY, Faller DV. Phosphorylation of Bcl-2 protein and association with p21Ras in Ras-induced apoptosis. J Biol Chem 1996;271:2376-9.
49. Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau VJ. Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem 1997;272:19022-6.
50. Ito T, Deng X, Carr B, May WS. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997;272: 11671-3.
51. Long BH, Fairchild CR. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 1994;54:4355-61.
52. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56: 816-25.
53. Lin HL, Chang YF, Liu TY, Wu CW, Chi CW. Submicromolar paclitaxel induces apoptosis in human gastric cancer cells at early G1 phase. Anticancer Res 1998;18:3443-9.
54. Milas L, Hunter NR, Kurdoglu B, Mason KA, Meyn RE, Stephens LC, et al. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with Taxol. Cancer Chemother Pharmacol 1995;35:297-303.
55. Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci U S A 1997;94:9679-83.
56. Moos PJ, Fitzpatrick FA. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA 1998;95:3896-901.
57. Ponnathpur V, Ibrado AM, Reed JC, Ray S, Huang Y, Self S, et al. Effects of modulators of protein kinases on Taxol-induced apoptosis of human leukemic cells possessing disparate levels of p26BCL-2 protein. Clin Cancer Res 1995;1: 1399-1406.
58. Wolfson M, Yang CP, Horwitz SB. Taxol induces tyrosine phosphorylation of Shc and its association with Grb2 in murine RAW 264.7 cells. Int J Cancer 1997;70:248-52.
59. Sorger PK, Dobles M, Tournebize R, Hyman AA. Coupling cell division and cell death to microtubule dynamics. Curr Opin Cell Biol 1997;9:807-14.
60. Li Y, Benezra R. Identification of a human mitotic checkpoint gene: hsMAD2. Science 1996;274:246-8.
61. Li Y, Gorbea C, Mahaffey D, Rechsteiner M, Benezra R. MAD2 associates with the cyclosome/anaphase-promoting complex and inhibits its activity. Proc Natl Acad Sci U S A 1997;94:12431-6.
62. Taylor SS, McKeon F. Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage. Cell 1997;89:727-35.
63. Taylor SS, Ha E, McKeon F. The human homologue of Bub3 is required for kinetochore localization of Bub1 and a Mad3/ Bub1-related protein kinase. J Cell Biol 1998;142:1-11.
64. Minshull J, Straight A, Rudner AD, Dernburg AF, Belmont A, Murray AW. Protein phosphatase 2A regulates MPF activity and sister chromatid cohesion in budding yeast. Curr Biol 1996;6:1609-20.
65. Minshull J, Sun H, Tonks NK, Murray AW. A MAP kinase-dependent spindle assembly checkpoint in Xenopus egg extracts. Cell 1994;79:475-86.
66. Martinez-Exposito MJ, Kaplan KB, Copeland J, Sorger PK. Retention of the bub3 checkpoint protein on lagging chromosomes. Proc Natl Acad Sci U S A 1999;96:8493-8.
67. Donaldson KL, Goolsby GL, Kiener PA, Wahl AF. Activation of p34cdc2 coincident with Taxol-induced apoptosis. Cell Growth Differ 1994;5:1041-50.
68. Huang TS, Shu CH, Yang WK, Whang-Peng J. Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331-induced apoptosis. Cancer Res 1997;57:2974-8.
69. Ibrado AM, Kim CN, Bhalla K. Temporal relationship of CDK1 activation and mitotic arrest to cytosolic accumulation of cytochrome C and caspase-3 activity during Taxol-induced apoptosis of human AML HL-60 cells. Leukemia 1998;12:1930-6.
70. Shen SC, Huang TS, Jee SH, Kuo ML. Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells. Cell Growth Differ 1998;9:23-9.
71. Furukawa Y, Iwase S, Terui Y, Kikuchi J, Sakai T, Nakamura M, et al. Transcriptional activation of the cdc2 gene is associated with Fas-induced apoptosis of human hematopoietic cells. J Biol Chem 1996;271:28469-77.
72. Meikrantz W, Schlegel R. Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases. J Biol Chem 1996;271:10205-9.
73. Harvey KJ, Blomquist JF, Ucker DS. Commitment and effector phases of the physiological cell death pathway elucidated with respect to Bcl-2 caspase, and cyclin-dependent kinase activities. Mol Cell Biol 1998;18:2912-22.
74. Levkau B, Koyama H, Raines EW, et al. Cleavage of p21Cip1/ Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell 1998;1:553-63.
75. Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ, et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998;2:581-91.
76. Ling YH, Tornos C, Perez-Soler R. Phosphorylation of bcl-2 is a marker of M phase events and not a determinant of apoptosis. J Biol Chem 1998;273:18984-91.
77. Ling YH, Consoli U, Tornos C, Andreeff M, Perez-Soler R. Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with Taxol. Int J Cancer 1998;75:925-32.
78. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-31.
79. Yang DD, Kuan CY, Whitmarsh AJ, Rincon M, Zheng TS, Davis RJ, et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the JNK3 gene. Nature 1997;389:865-70.
80. Luo Y, Umegaki H, Wang X, Abe R, Roth GS. Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J Biol Chem 1998;273:3756-64.
81. Liu YF. Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. J Biol Chem 1998;273:28873-7.
82. Le-Niculescu H, Bonfoco E, Kasuya Y, Claret FX, Green DR, Karin M. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol Cell Biol 1999;19:751-63.
83. Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T, et al. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem 1998;273:4928-36.
84. Lee LF, Li G, Templeton DJ, Ting JP. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem 1998;273:28253-60.
85. Amato SF, Swart JM, Berg M, Wanebo HJ, Mehta SR, Chiles TC. Transient stimulation of the c-Jun-NH2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts. Cancer Res 1998;58:241-7.
86. Wang TH, Popp DM, Wang HS, Saitoh M, Mural JG, Henley DC, et al. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem 1999;274:8208-16.
87. Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C, et al. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J Biol Chem 1997;272:25238-42.
88. Srivastava RK, Mi QS, Hardwick JM, Longo DL Deletion of the loop region of bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 1999;96:3775-80.
89. Attalla H, Westberg JA, Andersson LC, Adlercreutz H, Makela TP. 2-Methoxyestradiol-induced phosphorylation of Bcl-2: uncoupling from JNK/SAPK activation. Biochem Biophys Res Commun 1998;247:616-9.
90. Lee LF, Schuerer-Maly CC, Lofquist AK, van Haaften-Day C, Ting JP, White CM, et al. Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Cancer Res 1996;56:1303-8.
91. Lee LF, Haskill JS, Mukaida N, Matsushima K, Ting JP. Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter. Mol Cell Biol 1997;17:5097-105.
92. Ling YH, Yang Y, Tornos C, Singh B, Perez-Soler R. Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells. Cancer Res 1998;58:3633-40.
93. Lieu CH, Chang YN, Lai YK. Dual cytotoxic mechanisms of submicromolar Taxol on human leukemia HL-60 cells. Biochem Pharmacol 1997;53:1587-96.
94. Pulkkinen JO, Elomaa L, Joensuu H, Martikainen P, Servomaa K, Grenman R. Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. J Cancer Res Clin Oncol 1996;122:214-8.
95. Liu Y, Bhalla K, Hill C, Priest DG. Evidence for involvement of tyrosine phosphorylation in Taxol-induced apoptosis in a human ovarian tumor cell line. Biochem Pharmacol 1994; 48:1265-72.
96. Carles G, Braguer D, Sabeur G, Briand C. The effect of combining antitubulin agents on differentiated and undifferentiated human colon cancer cells. Anticancer Drugs 1998;9:209-21.
97. Lieu CH, Liu CC, Yu TH, Chen KD, Chang YN, Lai YK. Role of mitogen-activated protein kinase in Taxol-induced apoptosis in human leukemic U937 cells. Cell Growth Differ 1998;9:767-76.
98. Rieder CL, Schultz A, Cole R, Sluder G. Anaphase onset in vertebrate somatic cells is controlled by a checkpoint that monitors sister kinetochore attachment to the spindle. J Cell Biol 1994;127:1301-10.
99. Toczyski DP, Galgoczy DJ, Hartwell LH. CDC5 and CKII control adaptation to the yeast DNA damage checkpoint. Cell 1997;90:1097-106.
100. Wang Y, Burke DJ. Cdc55p, the B-type regulatory subunit of protein phosphatase 2A, has multiple functions in mitosis and is required for the kinetochore/spindle checkpoint in Saccharomyces cerevisiae. Mol Cell Biol 1997;17:620-6.
101. Wilson L, Jordan MA. Pharmacological probes of microtubule function. In: Hyams JS, Lloyd CW, editors. Microtubules. Volume 13. New York: John Wiley and Sons, Inc., 1994;59-83.
102. Suffness M. Is Taxol a surrogate for a universal regulator of mitosis? In Vivo 1994;8:867-78.
103. Derry WB, Wilson L, Jordan MA. Substoichiometric binding of Taxol suppresses microtubule dynamics. Biochemistry 1995;34:2203-11.
104. Waters JC, Mitchison TJ, Rieder CL, Salmon ED. The kinetochore microtubule minus-end disassembly associated with poleward flux produces a force that can do work. Mol Biol Cell 1996;7:1547-58.
105. Derry WB, Wilson L, Jordan MA. Low potency of Taxol at microtubule minus ends: implications for its antimitotic and therapeutic mechanism. Cancer Res 1998;58:1177-84.
106. Sonnichsen DS, Relling MV. Chapter 17. Paclitaxel and docetaxel. In: Grochow LB, Ames MM, editors. A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics. Baltimore: Williams & Wilkins, 1998:375-94.
107. Uhr JW, Scheuermann RH, Street NE, Vitetta ES. Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 1997;3:505-9.
108. Bhalla K, Huang Y, Tang C, Self S, Ray S, Mahoney ME, et al. Characterization of a human myeloid leukemia cell line highly resistant to Taxol. Leukemia 1994;8:465-75.
109. Giannakakou P, Sackett DL, Kang Y-K, Zhan Z, Buters JTM, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-25.
110. Kavallaris M, Kuo DYS, Burkhart CA, Regl DL, Norris MD, Haber M, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997;100:1282-93.
111. Panvichian R, Orth K, Day ML, Day KC, Pilat MJ, Pienta KJ. Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res 1998;58:4667-72.
112. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998;273: 9357-60.
113. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A, et al. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits Taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 1997;42:73-81.
114. Ferlini C, Scambia G, Distefano M, Filippini P, Isola G, Riva A, et al. Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis. Br J Cancer 1997;75:884-91.
115. de Souza PL, Castillo M, Myers CE. Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine. Br J Cancer 1997;75: 1593-600.
116. Seong J, Milross CG, Hunter NR, Shin HC, Milas L. Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-alpha. Anticancer Drugs 1997;8:80-7.
117. Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to Taxol and epothilones. Proc Natl Acad Sci U S A 1998;95:1369-74.
118. Wang S, Guo CY, Castillo A, Dent P, Grant S. Effect of bryostatin 1 on Taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochem Pharmacol 1998;56: 635-44.
119. Simizu S, Tanabe K, Tashiro E, Takada M, Umezawa K, Imoto M. Potentiation of paclitaxel cytotoxicity by inostamycin in human small cell lung carcinoma, Ms-1 cells. Jpn J Cancer Res 1998;89:970-6.
120. Tishler RB, Geard CR, Hall EJ, Schiff PB. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992;52: 3495-7.
121. Geard CR, Jones JM, Schiff PB. Taxol and radiation. J Natl Cancer Inst Monogr 1993:89-94.
122. Choy H, DeVore RF III, Hande KR, Porter LL, Rosenblatt P, Yunus F, et al. Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer. Semin Oncol 1997;24(Suppl 12):21-6.
123. Milas L, Hunter NR, Mason KA, Kurdoglu B, Peters LJ. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res 1994;54:3506-10.
124. Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 1995;55:3564-8.
125. Gundersen GG, Cook AT. Microtubules and signal transduction. Curr Opin Cell Biol 1999;11:81-94.
126. Fussenegger M, Bailey JE. Molecular regulation of cell-cycle progression and apoptosis in mammalian cells: implications for biotechnology. Biotechnol Prog 1998;14:807-33.
127. Cassimeris L. Accessory protein regulation of microtubule dynamics throughout the cell cycle. Curr Opin Cell Biol 1999;11:134-41.